Observation of clinical efficacy of neoadjuvant chemotherapy regimen of TAC and AT in the treatment of triple negative breast cancer
10.3760/cma.j.issn.1008-6706.2017.07.009
- VernacularTitle:TAC方案与AT方案新辅助化疗治疗三阴性乳腺癌的临床疗效观察
- Author:
Guangzhang ZHAO
;
Haiying LIU
;
Jing LIU
;
Qilong LIU
- Keywords:
Chemotherapy,adjuvant;
Breast neoplasms;
Docetaxel
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(7):996-999
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect and adverse reaction of different neoadjuvant chemotherapy regimens:docetaxel + THP + cyclophosphamide and docetaxel + THP in the treatment of triple negative breast cancer.Methods The clinical data of 75 patients with triple negative breast cancer in type Ⅱa-Ⅲc period were retrospectively analyzed.According to different treatment method,they were divided into two groups.The observation group (43 cases)was given the treatment of TAC,the control group (32 cases) was given the treatment of AT.The short-term efficacy and adverse reaction were evaluated and analyzed before every course of treatment,the total effective rate was evaluated after four courses of treatment.The long-term curative effect of the two groups was evaluated by following-up.Results The total effective rate of the observation group was 90.70％,which was significantly higher than 71.88％ of the control group (x2 =4.536,P =0.033).The incidence rates of adverse effects of chemotherapy in the observation group were higher than the control group,but there were no statistically significant differences between the two groups (gastrointestinal disorder x2 =2.931,P =0.087;marrow depression x2 =1.586,P =0.208;baldness x2 =1.367,P =0.242;cardiotoxicx2 =1.114,P =0.291).The three years survival rates in the observation group and the control group were 93.02％ and 87.50％ respectively,there was no statistically significant difference between the two groups(x2 =0.940,P =0.332).Conclusion The neoadjuvant chemotherapy of TAC and AT is both effective in the treatment of triple negative breast cancer,and TAC scheme is superior to AT scheme,the long-term efficacy in the two schemes has no significant difference.
